Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15184715 | 1.00 | TRPA1 (0.44) | TRPA1SMN1; SMN2CYP2C19CYP1A2EPHX1 | |
| SCHEMBL15184700 | 1.00 | TRPA1 (0.44) | TRPA1SMN1; SMN2CYP2C19CYP1A2EPHX1 | |
| SCHEMBL10187476 | 0.89 | SRR (0.46) | CYP2C19SRRPTGS1TSHRTAAR1 | |
| SCHEMBL10187483 | 0.84 | PPARG (0.49) | SMN1; SMN2 | |
| SCHEMBL2691471 | 0.82 | TRPA1 (0.43) | TRPA1CYP1A2EPHX1SRRALPI | |
| SCHEMBL6479807 | 0.81 | CYP2C19 (0.41) | SMN1; SMN2CYP2C19CYP1A2TSHRSLC6A2 | |
| SCHEMBL24241172 | 0.80 | TRPA1 (0.43) | TRPA1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3239288 | 0.80 | DPP4 (0.45) | SMN1; SMN2CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL252676 | 0.80 | DPP4 (0.45) | SMN1; SMN2CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3904160 | 0.80 | DPP4 (0.45) | SMN1; SMN2CYP2C19SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002094753-A1 | OPTICALLY ACTIVE BENZYLALKYLCARBINOLS, THEIR PREPARATION AN D USE IN PERFUMERY | RHODIA CHIREX, INC. (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020177738-A1 | Novel optically active benzylalkylcarbinols, their preparation and use | RHODIA CHIREX INC. | 2002-11-28 | — | — | US | claimed |
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| EP-2542537-B1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2542537-B1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8513452-B1 | Brønsted acid-catalyzed asymmetric allylation and propargylation of aldehydes | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
| WO-2011107248-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107248-A1 | NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE | PHENEX PHARMACEUTICALS AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2002094753-A1 | OPTICALLY ACTIVE BENZYLALKYLCARBINOLS, THEIR PREPARATION AN D USE IN PERFUMERY | RHODIA CHIREX, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094753-A1 | OPTICALLY ACTIVE BENZYLALKYLCARBINOLS, THEIR PREPARATION AN D USE IN PERFUMERY | RHODIA CHIREX, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020177738-A1 | Novel optically active benzylalkylcarbinols, their preparation and use | RHODIA CHIREX INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020177738-A1 | Novel optically active benzylalkylcarbinols, their preparation and use | RHODIA CHIREX INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020177738-A1 | Novel optically active benzylalkylcarbinols, their preparation and use | RHODIA CHIREX INC. | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | RORB, RORC, RORA | TRPA1 876/4885SMN1; SMN2 2997/4885CYP2C19 1909/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | TRPA1 4045/4885SMN1; SMN2 951/4885CYP2C19 3178/4885 |
| US-20020177738-A1 | Novel optically active benzylalkylcarbinols, their preparation and use | CNR2, CNR1, PLD2 | TRPA1 827/4885SMN1; SMN2 3570/4885CYP2C19 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.